Glucosylceramide Synthase

Glucosylceramide synthase (GCS), converting ceramide to glucosylceramide, catalyzes the first reaction of ceramide glycosylation in sphingolipid metabolism. This glycosylation by GCS is a critical step regulating the modulation of cellular activities by controlling ceramide and glycosphingolipids (GSLs). An increase of ceramide in response to stresses, such as chemotherapy, drives cells to proliferation arrest and apoptosis or autophagy; however, ceramide glycosylation promptly eliminates ceramide and consequently, these induced processes, thus protecting cancer cells. Furthermore, persistently enhanced ceramide glycosylation can increase GSLs, participating in selecting cancer cells to drug resistance. GCS is overexpressed in diverse drug-resistant cancer cells and in tumors of breast, colon, and leukemia that display poor response to chemotherapy. As ceramide glycosylation by GCS is a rate-limiting step in GSL synthesis, inhibition of GCS sensitizes cancer cells to anticancer drugs and eradicates cancer stem cells.

Glucosylceramide Synthase 相关产品（7）

货号	产品名	Cas
PL04020	Glucosylceramide synthase-IN-1	2601393-20-6
PL04021	Glucosylceramide synthase-IN-2	2597958-02-4
PL04658	Ibiglustat	1401090-53-6
PL04659	Ibiglustat (L-Malic acid)	1629063-78-0
PL04660	Ibiglustat succinate	1629063-80-4
PL01856	Miglustat-d9 (hydrochloride)	1883545-57-0
PL03047	Sinbaglustat	441061-33-2